MedTrace Logo

Effect of Crestor on Lipoprotein Metabolism in Humans

NCT00214617 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-06-20

No results posted yet for this study

Summary

The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate the rate of removal of LDL from the blood. At the higher dose, the increased potency of Crestor is explained by a reduction in the production of LDL by the liver.

Conditions

Interventions

DRUG

Rosuvastatin at 5 mg/day and 40 mg/day

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Foundation for Atlanta Veterans Education and Research, Inc.

    lead OTHER

Principal Investigators

  • Anh Le, PhD · Emory University School of Medicine and Atlanta VAMC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214617 on ClinicalTrials.gov